Since then, mutations in IDH1 or IDH2 genes have been detected in many different tumors, primarily gliomas (>80% of grade II and grade III gliomas)5, acute myeloid leukemia (AML, ~15% of cases)6,7 and chondrosarcomas (~50% of cases)8. This evidence concerns the gene IDH2 and glioma.